Evidence map›Paper›PMID 39731449›Full record

ArticleBrain pathology (Zurich, Switzerland)2025

Protective role of Angiogenin in muscle regeneration in amyotrophic lateral sclerosis: Diagnostic and therapeutic implications.

Paola Fabbrizio, Sharada Baindoor, Cassandra Margotta, Junyi Su, Elena P Morrissey, Ina Woods, Marion C Hogg, Sara Vianello, Morten T Venø, Jørgen Kjems and 4 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paola FabbrizioLaboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Sharada BaindoorDepartment of Physiology and Medical Physics and SFI FutureNeuro Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
Cassandra MargottaLaboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Junyi SuOmiics ApS, Aarhus, Denmark.
Elena P MorrisseyDepartment of Physiology and Medical Physics and SFI FutureNeuro Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
Ina WoodsDepartment of Physiology and Medical Physics and SFI FutureNeuro Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
Marion C HoggDepartment of Physiology and Medical Physics and SFI FutureNeuro Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
Sara VianelloDepartment of Neuroscience, Azienda Ospedaliera di Padova, Padua, Italy.
Morten T VenøOmiics ApS, Aarhus, Denmark.
Jørgen KjemsInterdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Gianni SorarùDepartment of Neuroscience, Azienda Ospedaliera di Padova, Padua, Italy.
Caterina BendottiLaboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.ORCID 0000-0003-1055-1271
Jochen H M PrehnDepartment of Physiology and Medical Physics and SFI FutureNeuro Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0003-3479-7794
Giovanni NardoLaboratory of Neurobiology and Molecular Therapeutics, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.ORCID 0000-0002-1803-1484

Funding

Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica MUSALS-AChREU Joint Programme-Neurodegenerative Disease ResearchMinistero della Salute, Italy SG-2018-12366226Regione Lombardia CUP E48I20000000007Science Foundation Ireland 17/JPND/3455Science Foundation Ireland 20/SP/8953Science Foundation Ireland 21/RC/10294_P2Science Foundation Ireland CRT in Genomics Data Science 18/CRT/6214
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease with no effective treatments, in part caused by variations in progression and the absence of biomarkers. Mice carrying the SOD1G93A transgene with different genetic backgrounds show variable disease rates, reflecting the diversity of patients. While extensive research has been done on the involvement of the central nervous system, the role of skeletal muscle remains underexplored. We examined the impact of angiogenin, including its RNase activity, in skeletal muscles of ALS mouse models and in biopsies from ALS patients. Elevated levels of angiogenin were found in slowly progressing mice but not in rapidly progressing mice, correlating with increased muscle regeneration and vascularisation. In patients, higher levels of angiogenin in skeletal muscles correlated with milder disease. Mechanistically, angiogenin promotes muscle regeneration and vascularisation through satellite cell-endothelial interactions during myogenesis and angiogenesis. Furthermore, specific angiogenin-derived tiRNAs were upregulated in slowly progressing mice, suggesting their role in mediating the effects of angiogenin. These findings highlight angiogenin and its tiRNAs as potential prognostic markers and therapeutic targets for ALS, offering avenues for patient stratification and interventions to mitigate disease progression by promoting muscle regeneration.

Indexed as

Amyotrophic Lateral SclerosisMuscle, SkeletalRegenerationRibonuclease, PancreaticAgedAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicMiddle AgedMuscle DevelopmentangiogeninRibonuclease, Pancreaticamyotrophic lateral sclerosisAngiogeninbiomarkersskeletal muscletiRNAs

Identifiers

PMID39731449
PMCPMC12145901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.